|
|
 |
|
Viewing report
|
|
|
|
Boehringer Ingelheim: Performance, Products, Pipeline and Potential
Espicom Business Intelligence Ltd, Sep 2009, Pages: 120
Boehringer Ingelheim has remained family-owned since its inception in 1885, and continues to be one of the world’s leading 20 pharmaceutical companies in terms of pharmaceutical revenue. The company’s activities now encompass 138 affiliates in 45 countries, employing 41,300 people. These activities are concentrated on two businesses, that of Human Pharmaceuticals and Animal Health. Human Pharmaceuticals incorporates Prescription Medicines, Consumer Health Care and Industrial Consumer (which includes biotechnology manufacturing), meanwhile BI’s Ben Venue, Bedford and Roxane Laboratories (which operate as consolidated subsidiaries) compete in the global generics market. Consequently, BI has a strong foothold in each of the major types of pharmaceutical markets, and in 2008, all achieved sales growth with the exception of its Industrial segment. BI’s sales success was spread throughout the globe, with each of its three geographic segments (Europe, the Americas, and Asia/Australasia/Africa) also realising strong growth.
Branded prescription medicines remain BI’s most significant source of income. In 2008, this segment generated 74.7 per cent of total sales, principally driven by the success of Spiriva, Flomax and Micardis. In 2006, Abbot returned its US distribution rights for Mobic to BI due to increasing generic competition. Having once been a core part of BI's product portfolio, Mobic sales are now so low, the company no longer reports them. The losses experienced by Mobic were expected to dent BI's medium-term growth prospects, however, it now appears that the company has enough growth drivers to overcome this significant setback. Successful lifecycle management is expected to help Flomax and Sifrol continue to contribute strong sales in spite of patent loss and increased competition, thus avoiding the same fate as Mobic.
The launches of Aptivus and Cymbalta may prove vital for the Virology and CNS therapeutic areas, both of which are currently threatened by falling sales of their major products in the short-to-medium term. Aptivus and Cymbalta have been in-licensed through agreements with Pfizer and Eli Lilly, respectively, and BI continues to actively seek similar deals with other companies. However, in order to generate the maximum value from its product portfolio, BI will have to increase the productivity of its own R&D activities. Currently, BI’s pipeline is dominated by line extensions for its major products. In 2008, BI increased human pharma R&D expenditure by 21.9 per cent, and it now accounts for 17.4 per cent of total sales. Through this substantial investment, the company hopes to be able to broaden its research beyond effective lifecycle management of its major products. To this end, in 2005, new pharmaceutical compounds entered the Metabolic and Oncology pipelines, a notable milestone, as previously neither therapeutic area contained any pipeline projects.
In 1895, BI began using bacteria for the production of lactic acid, the first successful use of microorganisms for large-scale product manufacture. The company has since gone on to build a wealth of history and expertise in biotechnology, which could prove crucial as biopharmaceutical medicines become more prevalent in the prescription drugs market. BI does not currently market any major biologic products and biologic candidate compounds in the pipeline remain in the early stages of development. However, BI does have a number of research agreements in place which could help the company achieve its aspirations in this field. BI’s generates a substantial percentage of its income from contract manufacturing for other market leaders in biotechnology, including Amgen, Wyeth, MedImmune (AstraZeneca) and Pfizer. Should BI successfully bring to market a number of biologic products, the company will be adequately equipped with the infrastructure to exploit this emerging market in pharmaceuticals.
With over 200 years experience in the pharmaceutical market, BI remains a strong competitor. However, the company is entering a difficult transition period as it looks to refresh its product portfolio and bring new drugs to the market. Stability will come from its three core growth drivers in the short-to-medium term, but in the long-term, BI will be hoping for the successful introduction of new products. The company has developed the infrastructure and capacity to support such ambitions, and established several prosperous collaborations with other major pharmaceutical companies, which will provide further support and opportunities for growth.
This new strategic analysis report Boehringer Ingelheim: Pipeline - Products - Performance - Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
REPORT CONTENTS
EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.
THERAPEUTIC AREA FOCUS
Key product analysis and forecasting
Respiratory
Combivent (ipratropium bromide+albuterol)
Spiriva (tiotropium bromide)
Cardiovascular
Aggrenox (dypyridamole+acetylsalicylic acid)
Micardis (telmisartan)
Pradaxa (dabigatran)
Urology
Flomax/Alna (tamsulosin)
Central Nervous System
Cymbalta/Xeristar (duloxetine)
Sifrol/Mirapex/Mirapexin (pramipexole)
Virology
Aptivus (tipranavir)
Viramune (nevirapine)
OPERATIONAL DATA
A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Infrastructure
Subsidiaries and joint ventures
|
|
|
|
